Heron Therapeutics (HRTX) Stock Forecast & Price Target

Heron Therapeutics is viewed positively because ZYNRELEF appears to be gaining commercial traction, with targeted-account unit volume rising from about 9,000 units before IGNITE to more than 19,000 units by 4Q25, a 111% increase within the targeted base. The expanded IGNITE footprint from 2,261 to 3,109 accounts, near-90% CrossLink alignment, and planned sales-force expansion should improve coverage, account depth, and pull-through where formulary access and payer coverage already exist. While the 6/1/26 CINVANTI patent ruling creates a generic-launch overhang, strong Exparel clinical results and the need for sequential ZYNRELEF revenue progression from 2Q26 through 4Q26 support a constructive fundamental outlook.

Heron Therapeutics is facing a deteriorating fundamental setup as ZYNRELEF’s slower-than-expected ramp and APONVIE’s commercialization have not yet offset reliance on CINVANTI, which represents about 60% of topline and has historically funded investment in the rest of the portfolio. The June adverse patent ruling on CINVANTI increases the likelihood of generic erosion, with expectations that sales could fall by roughly 50% over time, while the company has already withdrawn its $173–183M revenue and $10–20M Adjusted EBITDA guidance and paused planned spending expansion. With only $42.7M of cash at 2Q26 against about $142.7M of debt, plus covenant resets and principal reduction requirements through 2027, liquidity, leverage, and execution risk now overshadow the company’s standalone growth prospects.